Corbus Pharmaceuticals Holdings, Inc.
NASDAQ•CRBP
CEO: Dr. Yuval Cohen Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-10-27
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Contact Information
Market Cap
$119.21M
P/E (TTM)
-1.6
17.5
Dividend Yield
--
52W High
$20.56
52W Low
$4.64
52W Range
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$1.25+0.00%
4-Quarter Trend
FCF
-$15.93M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
CRB-701 Clinical Advancement CRB-701 data presented at ESMO25; FDA meeting planned Q1 2026 for HNSCC/cervical registration.
CRB-913 Obesity Trial Progress Phase 1a completed; Phase 1b CANYON-1 study initiated December 2025, completion expected Summer 2026.
R&D Spending Increased 118% R&D expense reached $70.1M USD in 2025, up 118% from $32.2M USD, focusing on pipeline advancement.
Cash Position Maintained Total cash, equivalents, investments stood at $163.3M USD as of December 31, 2025, supporting operations.
Risk Factors
Net Loss Significantly Widened Net loss reached $78.5M USD in 2025, substantially increasing from $40.2M USD loss in prior year.
Continued Need for Capital Expect continued operating losses; substantial additional financing required to fund ongoing pre-clinical and clinical development.
Reliance on Third-Party Manufacturing Complete dependence on contract manufacturers for cGMP supply; failure risks halting development or commercialization efforts.
CRB-601 Program Deprioritized CRB-601 program deprioritized; company will not enroll additional patients in the Phase 1 dose escalation study.
Outlook
Advance CRB-701 Regulatory Path Expect meeting with FDA in Q1 2026 to discuss clinical data and registrational study protocols for CRB-701.
Complete CRB-913 Phase 1b Study CANYON-1 Phase 1b dose-range finding study completion expected in Summer 2026 for obesity candidate.
Manage Operating Cash Runway Current cash ($163.3M USD) expected to fund operations for at least twelve months from filing date.
Maintain Nasdaq Listing Compliance Must satisfy Nasdaq continued listing requirements; failure risks delisting, impairing liquidity and financing ability.
Peer Comparison
Revenue (TTM)
$126.71M
$70.39M
$53.43M
Gross Margin (Latest Quarter)
100.0%
100.0%
100.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| GNFT | $445.68M | -11.0 | -63.7% | 64.1% |
| PEPG | $369.77M | -2.5 | -75.7% | 9.8% |
| FBRX | $343.99M | -9.4 | -75.6% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 4, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data